Core Insights - The overall ETF market has seen significant growth in both share and asset scale in the first half of 2025, with a total non-monetary ETF share of 4.3 trillion yuan, an increase of over 500 billion yuan since the beginning of the year [2][4]. Group 1: Bond ETFs - Bond ETFs emerged as the top-selling category in the first half of the year, with 29 funds contributing nearly 160 billion yuan in sales [2][3]. - The total net inflow for bond ETFs reached approximately 159.6 billion yuan, with the Hai Fu Tong Zhong Zheng Short-term Bond ETF (511360) leading with an inflow of nearly 19 billion yuan [4][5]. - The surge in bond ETF popularity is attributed to increased demand for stable returns amid an asset shortage, with investors favoring medium-term, high-rated credit bonds [5]. Group 2: Commodity ETFs - Commodity ETFs achieved a return of 20.48%, primarily driven by gold ETFs, which significantly outperformed other commodities [6][7]. - The largest gold ETF, Hua An Gold ETF (518880), saw inflows exceeding 20 billion yuan, more than double that of the second-largest [9]. - The rise in gold prices is linked to heightened market uncertainty and increased demand for safe-haven assets due to global geopolitical tensions [10]. Group 3: Cross-Border ETFs - Cross-border ETFs experienced an 18% increase, largely due to strong performance in Hong Kong stocks, particularly in the pharmaceutical, dividend, and technology sectors [11][12]. - The top-performing cross-border ETF, Fu Guo Zhong Zheng Hong Kong Stock Connect Internet ETF (159792), recorded a net inflow of nearly 19 billion yuan [12]. - The Hong Kong stock market's daily trading volume has reached a historical high, contributing to the strong performance of cross-border ETFs [13]. Group 4: Stock ETFs - Core broad-based stock ETFs, particularly the CSI 300 ETFs, have shown robust inflows, with the top two ETFs each exceeding 20 billion yuan in net inflows [14][15]. - The overall trend indicates a stable performance in the stock ETF market, supported by government interventions and a strong demand for core assets [16].

Group 1 - The Hong Kong stock market is increasingly recognized as a vital platform for capital operations, particularly in fund investment exits and mergers and acquisitions (M&A) [1][3] - The Hong Kong Company Secretarial Association emphasizes the importance of Hong Kong as a key international market for asset restructuring and fund exits for Chinese enterprises [1] - Recent discussions highlighted the growing trend of diversified exit strategies for investment institutions due to declining IPO valuations and increased liquidity demands [3] Group 2 - Legal experts discussed critical issues for funds and financial investors when exiting through the Hong Kong stock market, including special shareholder rights and compliance with Hong Kong Stock Exchange regulations [5] - The importance of understanding the differences in lock-up periods for various types of investors during the IPO stage was emphasized [5] - The regulatory requirements for cornerstone investors in the IPO process were outlined, along with potential exemptions [5] Group 3 - Cross-border M&A legal due diligence now requires a focus on trade compliance and risks associated with economic sanctions [7] - Geopolitical factors may lead to stricter antitrust reviews and foreign investment scrutiny in cross-border transactions [7] - Key clauses in M&A agreements may vary by region, with a trend towards enhanced guarantees and indemnities to increase transaction certainty [7] Group 4 - Recent updates to the Hong Kong Stock Exchange guidelines have introduced specific requirements for valuation disclosures in transactions [9][10] - Various valuation methods were discussed, including their principles, applicability, and key considerations during practical implementation [10] - Tax considerations for fund exits and M&A were addressed, including the tax treatment of RMB and USD fund structures [11]

【导读】香港公司治理公会、安永、奋迅 · 贝克麦坚 时等 详解港股基金退出与并购秘籍 中国基金报记者 卢鸰 香港公司治理公会北京代表处首席代表高伟在开幕致辞中表示，香港不仅是中国企业的 IPO 市场，也正在成为中国企业资产重组、收购兼并，以及基金退出的最为重要的国际市场，公 会愿意与合作伙伴一起，共同助力更多的内地企业有效利用香港的市场化机制实现高质量发 展。 并购退出方式正在蓄势 在此次研讨会上，安永华北区战略与交易咨询主管合伙人朱盎以最新市场数据，阐述了近年 中国股权投资市场退出的分布特征，包括方式、行业、地区等方面。 2024 年 1 月至今，香港恒生指数最高涨幅达 65.43% 。在此背景下，作为重要的资本运作 平台，在基金投资退出与企业并购领域，港股市场的作用愈发凸显。 6 月 24 日， " 港股市场的进与退：基金投资退出路径与并购实务 " 专题研讨会在北京安永 大楼成功举办，此次研讨会由中国基金报、安永（中国）咨询有限公司北京分公司、奋迅 · 贝克麦坚时律师事务所及思治企业咨询联合主办。 围绕港股市场基金退出策略与并购实务，香港公司治理公会、安永、奋迅 · 贝克麦坚时等机 构与会者进行了深度探讨 ...

Core Viewpoint - The Hong Kong IPO market is experiencing a significant resurgence, highlighted by multiple companies going public simultaneously, indicating renewed investor confidence and interest in the market [3][12]. Group 1: Recent IPO Activity - On June 26, three companies, Zhou Li Fu, Sheng Bella, and Ying Tong Holdings, collectively rang the bell for their IPOs, marking a lively day for the Hong Kong stock exchange [1][7]. - Zhou Li Fu's IPO was oversubscribed by over 700 times, with a market capitalization exceeding 10.1 billion HKD, and it opened with a gain of over 18% [2]. - Sheng Bella, a high-end confinement center brand, had a market capitalization of nearly 40 billion HKD at its IPO, with its stock rising over 4% on debut [2][6]. - Ying Tong Holdings, which manages several luxury brands, had an IPO market capitalization of approximately 3.7 billion HKD [2][6]. Group 2: Market Trends and Statistics - The Hong Kong IPO market is projected to see around 40 companies debut in the first half of the year, raising approximately 1,087 billion HKD, representing a year-on-year increase of 33% in the number of IPOs and 711% in fundraising [9][10]. - The market is currently witnessing a surge in consumer companies going public, with significant names like Mi Xue Ice City and Hu Ming Tea already listed, reflecting a strong appetite for consumer stocks [10][11]. - As of June 24, over 160 companies are in the IPO queue, with a total refinancing scale reaching 1,428.54 million HKD, surpassing last year's total [11]. Group 3: Investor Sentiment and Future Outlook - There is a renewed confidence in the Hong Kong market, with investors showing increased interest in IPOs, driven by the performance of recent listings [14]. - The market is expected to see a revaluation of Chinese assets, particularly in consumer stocks, as international capital shows a growing interest [14][15]. - Companies are encouraged to accelerate their IPO plans, as the current window for accessing international capital markets is perceived to be limited [16].

港股IPO与国际化：资本服务产业的战略落子 牧原股份于2025年5月27日正式向香港联交所递交H股上市申请，标志着其国际化战略迈出关键一步。 企业表示，港股上市的核心诉求并非单纯融资，而是为未来五年到十年的海外业务铺路。 东南亚市场成为牧原出海的首站。以越南为例，当地养殖企业在装备研发、疫病防控等领域存在技术缺 口，这为牧原的技术服务输出提供了空间。2024年，牧原与越南企业BAF达成战略合作，从猪场设计、 设备供应到人员培训形成完整服务链条。目前，牧原越南子公司已投入运营，未来计划探索更多合作模 式，将国内验证过的除臭灭菌工艺、智能装备等解决方案复制到海外。 港股上市与国际化业务形成双向助力。香港作为国际金融中心，能够提升牧原在全球市场的信任度与品 牌认知，而海外业务拓展也将为资本市场提供增量叙事。根据规划，港股募资将用于供应链建设、海外 并购及生物安全等研发投入，其中合成生物技术被视为抵御大豆价格波动、保障粮食安全的重要方向。 降本增效进入深水区：5月成本12.2元/kg背后的技术攻坚 2025年6月22日，牧原股份在第二十届养猪节媒体交流会上，全面展示了其在战略布局与经营管理上的 最新突破。作为全球生猪 ...

港股探底回升，恒生科技指数转涨，恒生指数跌幅收窄至0.5%。 ...

Group 1 - The core viewpoint of the article is that the correlation between Hong Kong stocks and A-shares has significantly increased since 2020, while the correlation with US stocks has weakened [1][2][3] - Historically, Hong Kong stocks were more correlated with US stocks, particularly from 1970 to 2020, but since 2020, this correlation has diminished, especially in 2021 and 2023 [1] - The increase in correlation between Hong Kong and A-shares is attributed to a decrease in foreign capital's share in Hong Kong stocks and an increase in domestic liquidity [1][2] Group 2 - Hong Kong stocks have become less dependent on overseas liquidity since 2020, with valuation contributing more to price movements, aligning with the increased correlation with A-shares [2] - The decline in foreign capital's share is influenced by geopolitical factors, currency arbitrage, and changes in the price-performance ratio of Hong Kong stocks [2] - Domestic capital has accelerated its inflow into Hong Kong stocks due to price advantages and scarcity of investment targets, further linking Hong Kong's liquidity to mainland capital behavior [2] Group 3 - The fundamental performance of Hong Kong stocks is increasingly related to mainland China, with over two-thirds of listed companies being Chinese enterprises, contributing 90% of net profits [3] - The proportion of mainland enterprises listed in Hong Kong has risen since 2020, supported by policies aimed at developing Hong Kong's capital market [3] - The correlation between Hong Kong stocks and overseas markets has weakened, with less impact from changes in overseas demand and economic cycles since 2020 [3]

今年上半年，港股"股王"老铺黄金（06181）股价一度触及高点1015港元，截至6月25日收盘，该股年内涨幅近270%，上市以来累计飙升超倍，成为资 本市场的现象级案例。市场普遍关注的是，同样聚焦高端黄金产品、且渠道下沉能力更胜一筹的周六福（06168），能否复制老铺黄金的估值神话？ 根据智通财经APP了解，周六福暗盘平开高走，涨幅曾高达15.21%，收涨12.92%，报27.1港元，成交额1.55亿港元，总市值115.32亿港元。每手100股， 不计手续费，每手赚310港元。 594倍超额认购备受资金追捧 触发套路回拨难挡"入通"势头？ 公开资料显示，周六福此次IPO计划全球发售4680.8万股（占全球发售完成后11%，另有15%发售量调整权），其中香港发售468.08万股，国际发售 4212.72万股，另有15%超额配股权，发售价为每股24.00港元，每手100股，预计募资总额11.23亿港元，IPO市值约为102.13亿港元。本次IPO保荐人为中 金公司和中信建投国际。 在本次IPO发行中，周六福总计引入8名基石投资者，累计认购约5.73亿港元——其中，深圳罗湖国资认购2亿人民币、永诚资本认购1.1亿港 ...

多重利好共振，港股吸引力持续提升 2025 年，港股市场展现出超预期的韧性，特别是在宏观经济不确定性逐步缓解的背景下，南向资金的持续流入成为 港股上行的关键动力。截至今年 6 月 19 日，南向资金累计净买入港股的金额已突破 6960.41 亿港元，相当于 2024 年 全年南向资金净买入额的 86.16%。根据近五年数据，南向资金的流入逐年上升，尤其在 2024 年和 2025 年，资金流 入的同比增速分别达到了 172.27%和 98.87%。这一增长趋势反映了全球投资者对港股的信心不断增强，同时也表明 港股市场具备较强的吸引力。除南向资金外，港股的估值在全球股市中表现出低估优势。截至 2025 年 6 月 19 日，恒 生综合指数的市盈率为 11.3 倍，显著低于标普 500 和中证全指。这种低估值使得港股的投资性价比愈发突出，成为 全球投资者关注的重点。此外，随着全球经济的不确定性逐步缓解，资金流动趋向于从低收益的固定收益资产流向 高回报的风险资产。美联储预计在 2025 年下半年可能会启动降息周期，合并美元走弱趋势，将进一步推动资本流向 包括港股在内的市场，为港股提供了有利的外部环境。综合来看，港股 ...

Core Viewpoint - The rising public awareness of autoimmune diseases, particularly ankylosing spondylitis, has led to increased interest in the pharmaceutical company Ganzhou Hemei Pharmaceutical Co., Ltd. as it seeks to go public with its core drug Mufemilast targeting psoriasis and ankylosing spondylitis [1][6]. Company Overview - Ganzhou Hemei Pharmaceutical is preparing for an IPO under the Hong Kong Stock Exchange's 18A biotechnology rules, focusing on high investment and potential returns typical of biopharmaceutical companies [2]. - The company has not yet generated revenue and relies heavily on government subsidies and continuous financing to sustain operations [2][11]. Product Pipeline - The company has seven clinical-stage small molecule candidates aimed at addressing unmet medical needs in autoimmune diseases and oncology [2]. - Mufemilast is a dual-action PDE4 inhibitor that has entered the NDA priority review process, targeting multiple indications including psoriasis and ankylosing spondylitis [2][3]. Market Potential - The market for psoriasis drugs in China has seen rapid growth, with a compound annual growth rate (CAGR) of 30.4% from 2019 to 2023, reaching a market size of 13.9 billion yuan in 2023, projected to soar to 89.4 billion yuan by 2032 [3]. - The autoimmune disease drug market in China has expanded from $2.5 billion in 2019 to $4 billion in 2023, with expectations to reach $26.3 billion by 2032, reflecting a CAGR of 23.3% [6]. Competitive Landscape - The competitive environment for Mufemilast is intense, with existing competitors having undergone significant price reductions due to national procurement policies, with price drops exceeding 93% for some products [5]. - There are currently five approved small molecule targeted therapies for psoriasis in China, with 37 more in clinical development, indicating a crowded market for Mufemilast [5][8]. Financial Status - The company reported significant losses of 156 million yuan in 2023 and 123 million yuan in 2024, with minimal other income [11]. - The company has undergone multiple rounds of financing since 2021, raising over 500 million yuan to support its operations, with a post-investment valuation of 3.9 billion yuan [11]. Leadership - The founder and chairman, Zhang Hesheng, has over 20 years of experience in biopharmaceuticals and holds a significant voting power in the company [12].